User profiles for Carlos Almonacid
 | Carlos AlmonacidHospital Universitario Puerta de Hierro Majadahonda, Spain Verified email at separ.es Cited by 1076 |
The impact of COVID-19 on patients with asthma
JL Izquierdo, C Almonacid, Y González… - European …, 2021 - Eur Respiratory Soc
Background An association between the severity of coronavirus disease 2019 (COVID-19)
and the presence of certain chronic conditions has been suggested. However, unlike …
and the presence of certain chronic conditions has been suggested. However, unlike …
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma …
Background ANDHI was done to assess the efficacy of benralizumab, including onset of effect
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …
[HTML][HTML] REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma
Background Patients with severe asthma may require maintenance oral corticosteroids (mOCS)
for disease control as well as systemic corticosteroid (SCS) bursts for clinically …
for disease control as well as systemic corticosteroid (SCS) bursts for clinically …
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms …
…, J Domínguez-Ortega, C Almonacid… - The Journal of Allergy …, 2021 - Elsevier
… Almonacid has participated in speaking activities, advisory committees, and consultancies
sponsored by AstraZeneca, Boehringer-Ingelheim, Chiesi, Menarini, GSK, ALK Mundipharma…
sponsored by AstraZeneca, Boehringer-Ingelheim, Chiesi, Menarini, GSK, ALK Mundipharma…
[HTML][HTML] Teleconsulta en el seguimiento del paciente con asma. Lecciones tras la COVID-19
C Almonacid, M Blanco-Aparicio… - Archivos de …, 2021 - ncbi.nlm.nih.gov
El asma es una enfermedad inflamatoria crónica de las vías respiratorias cuya prevalencia
en Espana es del 5% en los adultos y del 10% en la población infantil1. El objetivo del …
en Espana es del 5% en los adultos y del 10% en la población infantil1. El objetivo del …
Misdiagnosis of patients receiving inhaled therapies in primary care
…, C Almonacid… - … journal of chronic …, 2010 - Taylor & Francis
Aim To analyze the accuracy of diagnosis in a population receiving inhaled therapies due to
respiratory diseases in a primary care setting. Method Noninterventional, multicenter, cross-…
respiratory diseases in a primary care setting. Method Noninterventional, multicenter, cross-…
[HTML][HTML] Estudio de prevalencia de asma en población general en España
…, JG Soto-Campos, I Urrutia-Landa, C Almonacid… - Open Respiratory …, 2023 - Elsevier
Introducción El asma es una enfermedad con elevada prevalencia, que afecta a todos los
grupos de edad y genera elevados costes sociosanitarios. Estudios realizados en diversas …
grupos de edad y genera elevados costes sociosanitarios. Estudios realizados en diversas …
A proposed approach to chronic airway disease (CAD) using therapeutic goals and treatable traits: a look to the future
…, C Cisneros, C Almonacid… - … Journal of Chronic …, 2020 - Taylor & Francis
Chronic airflow obstruction affects a wide range of airway diseases, the most frequent of which
are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but …
are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but …
[HTML][HTML] Neumomediastino espontáneo en pacientes con COVID-19: una serie de cuatro casos
…, P Arrieta, C Almonacid-Sánchez… - Archivos de …, 2020 - ncbi.nlm.nih.gov
La enfermedad por SARS-CoV-2 (COVID-19) es una infección causada por un nuevo coronavirus
emergente detectado por primera vez en Wuhan (China) en diciembre de 2019. En la …
emergente detectado por primera vez en Wuhan (China) en diciembre de 2019. En la …
Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors
…, A El Hachem, D Graziani, C Almonacid… - … journal of chronic …, 2014 - Taylor & Francis
While it is relatively well known that the prognosis of patients with lung cancer (LC) treated
with surgery is worse in the presence of chronic obstructive pulmonary disease (COPD), it is …
with surgery is worse in the presence of chronic obstructive pulmonary disease (COPD), it is …
